COMP <GO>
INDV vs UNH // REVENUE GROWTH (YOY)
Indivior Pharmaceuticals Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: INDV 6
— UNH 9
▲ REVENUE GROWTH (YOY) LEADER: UNH
LAST: $35.37 (+0.34%) • MKT CAP: $4.16B
revenue-growth
4.30%
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
revenue-growth
6.46%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INDV VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INDV | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 80.20% | 88.57% | -8.37 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 62.20% | 11.47% | +50.73 | INDV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 13.4x | 16.4x | -3.05 | INDV | /valuation <GO> |
| Free Cash Flow Yield | -2.24% | 6.48% | -8.72 | UNH | /fcf-yield <GO> |
| Operating Margin | 21.10% | 4.82% | +16.28 | INDV | /operating-margins <GO> |
| Net Profit Margin | 16.90% | 3.14% | +13.76 | INDV | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 4.30% | 6.46% | -2.16 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.13 | 3.12 | +0.01 | INDV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 6.74% | +0.66 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.2 | 56.0 | -3.81 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 0.33 | +0.82 | INDV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.4x | 17.1x | +1.31 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.16B | $364.66B | -$360.50B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INDV REV | UNH REV | INDV GROSS % | UNH GROSS % | INDV FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.24B | $447.57B | 80.2% | 88.7% | -$93.0M | $16.07B |
| FY 2024 | $1.19B | $400.28B | 80.6% | 88.3% | $7.0M | $20.70B |
| FY 2023 | $1.09B | $371.62B | 44.0% | 89.6% | -$349.2M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INDV // BETA 1.15
UNH // BETA 0.33